Introduction
Inherited platelet function disorder (IPFD) or thrombocytopathies are hereditary disorders of platelet that can be classified into platelet adhesion disorders, platelet aggregation disorders, platelet activation disorders, platelet secretion disorders, and platelet procoagulant function disorders. Bernard–Soulier syndrome (BSS) is a platelet adhesion disorder caused by a deficiency of glycoprotein Ib-IX-V complex (Von Willebrand factor receptor). These defects can be quantitative or qualitative. It has a prevalence of 1 in 1 million individuals [1] affecting both males and females. The mutations are a point or a frameshift type resulting in premature stop codon leading to deficiency of the membrane glycoproteins. This defective primary haemostasis can cause bleeding from mucocutaneous sites, menorrhagia, and bleeding in the antepartum, intrapartum, and postpartum period. Pregnant women with these spectra of disorders are considered high risk and should be managed at a tertiary care centre with an availability of a multispecialty team. We report our experience in handling such a pregnant woman.
Case Report
A 26-year-old primigravida, a known case of Bernard–Soulier syndrome conceived by ovulation induction, came to our hospital in labour for the first time at 38 + 6 weeks of gestation. She was born out of non-consanguineous marriage with no family history of bleeding disorders. She had bleeding gums while brushing and irregular cycles once in 3 months after attaining menarche, which was managed with oral contraceptives intermittently without evaluation. At the age of 21, she had heavy menstrual bleeding with severe anaemia managed with blood transfusions, tranexamic acid, and medroxyprogesterone acetate, during which she was found to have Bernard–Soulier syndrome. Investigations at the time of diagnosis are given in Table 1. Antenatally, she did not have any bleeding episodes. Due to her late presentation at term, she had not received any genetic counselling. At admission, her haemoglobin was 12.8 g/dl, platelet count of 1,53,000 per cu. mm with average bleeding time. The routine antenatal investigations were normal. There were no signs of bleeding diathesis on examination, and the uterus corresponded to term gestation with a live foetus in breech presentation. An emergency caesarean under general anaesthesia was done on the same day because of breech in labour and delivered a healthy female baby of 2.5 kg. The intraoperative blood loss was 300 ml. Though uneventful, she received prophylactic random donor platelet transfusions, four preoperatively and four intraoperatively. The neonate platelet count was 1,70,000 per cu. mm with no bleeding manifestations. Her postoperative period was uneventful and was discharged on postoperative day 7 with further follow-up in haematology and postnatal clinics.
Table 1.
Investigations at the time of diagnosis
Tests | Patient’s value | Reference Range |
---|---|---|
Haemoglobin (g/dl) | 6.5 | 12.1–15.1 |
Platelet count (per cu. mm) | 1,10,000 | 1,50,000–3,50,000 |
Platelet morphology | Few giants | Biconvex discoid |
Bleeding time (minutes) | 11.5 | 2.0–9.0 |
Clotting time (minutes) | 4.5 | 2.0–8.0 |
PT (seconds) | 14.4 | 11.1–14.5 |
aPTT (seconds) | 30.7 | 28.1–39.7 |
INR | 1.2 | 0.8–1.1 |
vWF: RCO assay (IU/dl) | 103 | 50–200 |
Platelet aggregation studies (%) | ||
Ristocetin | 8 | 64 |
ADP | 80 | 54 |
Epinephrine | 67 | 63 |
Collagen | 60 | 56 |
Flow cytometry | 67% of CD42b, 70% of CD42a, 94.5% of CD42d | ≥ 70.0% |
PT prothrombin time, aPTT activated partial thromboplastin time, INR international normalised ratio, vWF: RCO Von Willebrand Ristocetin Cofactor assay, ADP adenosine diphosphate
Discussion
Bernard–Soulier syndrome was described by Jean Bernard and Jean Pierre Soulier in 1948. Glycoprotein Ib-IX-V complex is a Von Willebrand factor receptor which is deficient in BSS. The genes coding for GpIbα, GpIbβ, GpIX, and GpV are GP1BA, GP1BB, GP9, and GP5 and are located in chromosomes 17, 22, and 3 respectively, with markers CD42b, CD42a, CD42d respectively.
We performed an electronic search on PubMed, Embase, Cochrane, Scopus, Science Direct, and Google scholar using the word combinations: ‘Bernard-Soulier’ AND ‘pregnancy’ OR ‘gestation’; the articles published only in English and between 2000 and till date were included. We identified 24 relevant articles which fit into our search criteria. After thoroughly evaluating the abstracts, 15 articles were excluded, and nine were included (Table 2). A total of 12 patients and 19 pregnancies were reviewed. Most women were primigravida (60%), commonly presented in the third trimester. The average platelet count was 49,500 per cu. mm. Caesarean section was the common mode of delivery in 78.6% of individuals. Platelet transfusions were given intrapartum in all the cases. Few received tranexamic acid, but desmopressin (DDAVP: 1-desamino-8-d-arginine vasopressin), recombinant factor VIIa (r-VIIa), and intravenous immunoglobulin (IVIG) were used rarely. Thrombocytopenia was detected in 22.2% of the neonates, the cause being alloimmunisation which required platelet transfusions and immunoglobulins. Cordocentesis was performed on two patients [2].
Table 2.
Literature review of pregnant women with Bernard-Soulier syndrome
Author name and year | Age | Obstetric index and Gestational age | Consanguinity | Age at diagnosis (years) | Platelet count at the time of diagnosis (per cu. mm) | Clinical features at the time of diagnosis | Treatment prior to pregnancy | Platelet count during pregnancy (per cu. mm) | Mode of delivery and anaesthesia | Management during pregnancy/post-partum | Maternal complications | Neonatal outcome |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Kriplani, 2005 | 31 |
G2A1 37 weeks |
First degree cousins consanguineous | 15 |
Menorrhagia Spontaneous bruising |
Three units of blood Haemostatic agents Oral contraceptive pills |
47,000 | Elective caesarean i/v/o borderline mid-pelvis |
2 PRBC 1 SDP 6 RDP Tranexamic acid 500 mg IV TDS Uterotonics |
Primary PPH | Normal platelet count | |
Previous spontaneous abortion, 8 weeks | D and C done | Uneventful | ||||||||||
Rahimi, 2005 | 22 |
G1 34 weeks |
Menorrhagia | 17,000 | Elective LSCS | Multiple blood and blood products |
Anaemia Secondary PPH |
Healthy | ||||
Prabhu, 2006 |
23 17 |
25 weeks | Consanguineous | 23 | Bruising | Blood transfusion ten years before for nasal bleed | 37,000 | Ventouse |
10 PRBC 12 ATD of platelet Tranexamic acid 1 g TDS IV DDAVP single dose |
Primary PPH Secondary massive PPH |
Normal platelet count | |
Multigravida 41 weeks |
Consanguineous | 12 | 14,000 |
Bruising Recurrent nasal bleed Menorrhagia |
Vaginal |
4 PRBC 8 ATD of platelet Oral tranexamic acid 1 g TDS |
Secondary PPH | |||||
Previous pregnancy 40 weeks |
Vaginal |
4 ATD of platelet Oral tranexamic acid 1 g TDS 4 PRBC |
Antepartum haemorrhage Primary PPH |
|||||||||
Zafar, 2007 | 26 | 5 weeks of gestation | 26 |
Epistaxis Menorrhagia Intra-peritoneal bleed Haemorrhagic shock |
Multiple blood and platelet transfusions | 23,000 | Elective LSCS i/v/o abnormal doppler, pre-eclampsia at 37 weeks |
Prophylactic 1 PRBC and 1 SDP Uterotonics |
Minor gum bleed Pre-eclampsia Foetal growth restriction |
Platelet count: 2.6 lakh/cu.mm | ||
Uotila, 2008 | P3L3 | 19 |
Recurrent epistaxis Excessive bleeding after tonsillectomy |
Splenectomy Steroids |
19,000 to 1.09 lakh | LSCS i/v/o failed induction |
IVIG Platelet transfusion Cordocentesis |
Recurrent epistaxis | Normal platelet count | |||
P3L3 | 21 | 10,000 |
Ecchymosis Recurrent epistaxis |
Splenectomy Steroids Azathioprine IVIG Platelet transfusion |
10,000 to 1 lakh | Elective LSCS i/v/o foetal thrombocytopenia at 36 weeks |
IVIG Platelet transfusion Cordocentesis |
Primary and secondary PPH |
Platelet count: 8,000–16,000/cu.mm Platelet transfusion IVIG Prednisolone |
|||
Pascual, 2011 | 33 |
G2P1L1 32 weeks |
1.5 | Epistaxis | Multiple platelet transfusions | Emergency LSCS at 32 weeks i/v/o deteriorating maternal condition |
4 SDP 2 RDP |
Severe anaemia | Normal platelet count | |||
Previous pregnancy 38 weeks |
40,000 | Elective LSCS at 38 weeks | 4 SDP | Normal platelet count | ||||||||
Macedo, 2015 | 28 |
G1 39 + 4 weeks |
Consanguineous | 18 |
Epistaxis Gingival bleeding |
Prophylactic platelet transfusion | 43,000 | Elective LSCS under general anaesthesia | 10 prophylactic RDP | Minor gingival bleeding | Healthy | |
Perez, 2019 | 21 |
G1 33 + 4 weeks |
Consanguineous | 5 | Gingival bleed | 30,000 | Elective LSCS under general anaesthesia at 37 + 4 weeks |
21 platelet concentrates Tranexamic acid 10 mg/kg TDS |
Minor gingival bleed |
Platelet count: 53,000/cu.mm |
||
Demicri, 2021 | 24 |
G1 6 weeks |
Nasal bleed GIT bleeding |
6000 | Emergency LSCS under general anaesthesia i/v/o prolonged latent phase of labour |
Antepartum Multiple platelet transfusions Intrapartum 2 platelet transfusions r-VIIa 15mcg/kg Post-partum 3 PRBC 1 platelet 1 g carboxymaltose |
Epistaxis Gingival bleed Primary PPH |
Healthy Normal platelet count |
||||
The index case, 2022 | 26 |
G1 38 + 6 weeks |
Non-consanguineous | 21 | 1,10,000 | Heavy menstrual bleeding |
Blood transfusion Tranexamic acid Medroxyprogesterone acetate |
1,53,000 | Emergency LSCS under GA i/v/o breech in labour |
Prophylactic, 4 RDP preoperatively 4 RDP intraoperatively |
Uneventful |
Healthy Platelet count: 1,70,000 per cu. mm |
LSCS lower segment caesarean section, SDP single-donor platelet, RDP random donor platelet, PRBC packed red blood cells, IVIG intravenous immunoglobulins, PPH post-partum haemorrhage, ATD adult therapeutic dose, DDAVP desamino-d-arginine-vasopressin
Being autosomal recessive, only homozygous individuals manifest the disease, and the phenotypic trait may become visible, especially with consanguineous marriages. Although significant consanguinity was present in five reviewed studies, our case did not have a family history of a bleeding disorder, raising the possibility of denovo genetic mutation or carrier parents, which can be further analysed by genetic testing. BSS is usually diagnosed with mucocutaneous bleeding or menorrhagia in early childhood or adolescence. In our review, the mean age at diagnosis is 17.45 years, and epistaxis was the presenting symptom in 58.3%, followed by menorrhagia in 41.6% and skin bruising in 25%.
BSS is diagnosed with increased bleeding time with few giant platelets and low platelet count in the peripheral smear, average coagulation profile, defective platelet aggregation to ristocetin, normal aggregation to all platelet agonists, standard Von Willebrand Ristocetin Cofactor assay (vWF: RCO) and decreased CD42b, CD42a in flow cytometry as in our case.
The obstetric complications occurring in BSS can be either antepartum or postpartum haemorrhage. Primary or secondary postpartum haemorrhage (PPH) was reported in 33% of cases.
Management includes the use of antifibrinolytics, platelet transfusions, or rVIIa. Tranexamic acid is safe and effective in managing bleeding in pregnancy and postpartum. Though studies say that the role of prophylactic platelet transfusions is ineffective in preventing PPH [3], our case was effectively handled with prophylactic platelet transfusions providing functional platelets to the haemostatic system. Surgical intervention for PPH is rarely required. In patients with multiple platelet transfusions, anti-platelet antibody titre plays a role as the transplacental passage of IgG type of anti-platelet antibodies can lead to fatal neonatal alloimmune thrombocytopenia and refractoriness to fresh platelet transfusions. This increases the bleeding risk, necessitating the need for monitoring titre. However, it was not done in our patient due to presentation at term gestation. Alloimmunisation can be prevented by judicious use of leuco-depleted HLA-matched platelet transfusions [3]. The r-VIIa increases thrombin production, and fibrin deposition at the sites of vascular injury is an available alternative for patients who are refractory to platelet transfusions [4]. Steroids, intravenous γ globulins, and plasmapheresis can treat alloimmunised individuals. Though invasive prenatal tests can be performed, it is better avoided in patients with BSS as there is an increased risk of bleeding and uncertain foetal benefits with relatively scant data in the literature. Uotila [2] described cordocentesis in two patients to assess the severity of foetal thrombocytopenia and to decide on caesarean delivery for severe foetal thrombocytopenia.
Vaginal delivery is preferred, and care should be taken to avoid neonatal intracranial haemorrhage, mainly instrumental delivery. As in our case, general anaesthesia for caesarean delivery is generally indicated as there is a high risk of intrathecal bleed with regional anaesthesia.
Conclusion
Our patient was diagnosed with BSS in early adulthood during the evaluation of menorrhagia with flow cytometry findings of decreased CD42b and CD42a platelet surface markers. She had an uneventful antenatal period and presented to us at late gestation in labour. She received perioperative platelet transfusions without any adverse maternal or neonatal outcomes. She was managed by a multidisciplinary team involving obstetricians, anaesthesiologists, haematologists, and neonatologists and had a good pregnancy outcome.
Funding
Not applicable.
Declarations
Conflict of interest
The authors declare no conflicts of interest.
Informed consent
A written informed consent was obtained from the patient to publish their clinical details.
Human or Animal Rights
Not applicable.
Footnotes
Vignesh Durai is a senior resident, Department of Obstetrics and Gynaecology, Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Puducherry, India; Sathiyapriya Subburaj is a senior resident, Department of Obstetrics and Gynaecology, Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Puducherry, India; Murali Subbaiah is an additional professor, Department of Obstetrics and Gynaecology, Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Puducherry, India.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Wijemanne A, Watt-Coote I, Austin S. Glanzmann thrombasthenia in pregnancy: optimizing maternal and fetal outcomes. Obstet Med. 2016;9:169–170. doi: 10.1177/1753495X16655021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Uotila J, Tammela O, Mäkipernaa A. Fetomaternal platelet immunization associated with maternal Bernard-Soulier syndrome. Amer J Perinatol. 2008;25:219–223. doi: 10.1055/s-2008-1064932. [DOI] [PubMed] [Google Scholar]
- 3.Gresele P, Falcinelli E, Bury L. Inherited platelet disorders in women. Thromb Res. 2019;181:S54–S59. doi: 10.1016/S0049-3848(19)30368-8. [DOI] [PubMed] [Google Scholar]
- 4.Nurden AT. Acquired antibodies to α IIbβ3 in Glanzmann thrombasthenia: from transfusion and pregnancy to bone marrow transplants and beyond. Transfus Med Rev. 2018;32:155–164. doi: 10.1016/j.tmrv.2018.05.002. [DOI] [PubMed] [Google Scholar]